Investor Center Home


Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$20.85
Change Stock is Up 0.10
(%)Volume (0.48%)413,918
ExchangeNASDAQ
Data as of 09/28/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
09/20/16Bellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare ConferencePrinter Friendly Version
09/01/16Bellicum Pharmaceuticals to Present at the BioCentury 23rd Annual NewsMakers in the Biotech Industry ConferencePrinter Friendly Version
08/08/16Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/04/16Bellicum Announces BPX-501 European Regulatory UpdatesPrinter Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
09/27/16 10:00 a.m. ET
Bellicum Pharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference
Click here for webcast
Location: New York City
09/09/16 9:30 a.m. ET
Bellicum Pharmaceuticals Inc at BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference
Click here for webcast
Location: New York City
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources